HBEGF and leukemia: Moreover, aggressive cancers including leukemia and pancreatic adenocarcinomas exhibit significant upregulation of HBEGF (Figure S7, Supporting Information), warranting further investigations to assess HP‐NP clinical relevance beyond brain tumors.